热门资讯> 正文

Compass Therapeutics GAAP每股收益为-0.10美元在线

2026-05-05 19:35

Compass Therapeutics, Inc.(CMPX) 0

Compass Therapeutics press release (CMPX): Q1 GAAP EPS of -$0.10 in-line.
As of March 31, 2026, cash and marketable securities were $195 million as compared to $209 million as of December 31, 2025, a decrease of $14 million, with an anticipated cash runway into 2028. During the first quarter of 2026, $18 million of net cash was used in operating activities, and this was partially offset by proceeds from exercise of common stock of $4 million.

More on Compass Therapeutics

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Compass Therapeutics: Potential Here, But Patience Required
Compass Therapeutics plunges on tovecimig missing overall survival endpoint
Compass Therapeutics GAAP EPS of -$0.09
Seeking Alpha’s Quant Rating on Compass Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。